AbbVie Stock News

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

∴ Sponsored: Want to Retire Early?

AbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group's CEO will testify on Capitol Hill.

Everyone needs solace in stability and development in the current turbulent market climate. These are seven unwavering businesses that are well-known for their fundamental capability to withstand mark

WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting in

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

Investors rarely have a reason to ignore Dividend Aristocrat stocks. That's doubly true today with inflation remaining stubbornly high.

AbbVie and Johnson & Johnson have excellent dividend track records and solid businesses. However, one of these healthcare giants has a slight edge over the other.

AbbVie is an unstoppable passive income machine. Eli Lilly offers a sizzling stock performance and a growing dividend.

Drugmaker AbbVie topped sales and earnings expectations in Q1, although those expectations were modest. The leading products in its portfolio are changing quickly, which makes it difficult to determin

Shares of AbbVie (ABBV) slumped Friday as the pharmaceutical firm warned of deeper declines in sales of its blockbuster arthritis drug, Humira, because of competition from close copies known as biosim

AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.

While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to

AbbVie (ABBV) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.46 per share a year ago.

Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q1 financial results for 2024 today. AbbVie's earnings came in at $1.37 billion, or $0.77 per share, as compared with $239 million, or $0.13 pe